Latent autoimmune diabetes in adults: current concepts of risk factors, diagnosis, and therapy

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Slowly developing immune related diabetes mellitus of adults (LADA diabetes) is one of the most common types of atypical diabetes. LADA diabetes is a clinically and metabolically hybrid form of type 1 and 2 diabetes mellitus (DM) with a slowly progressive course. Due to its similarity in the early stages in clinical course with DM2 and in pathogenesis – with DM1, it is often overlooked in clinical practice. The article presents current criteria for the diagnosis of latent autoimmune diabetes in adults and describes differentiated tactics for choosing therapy.

Full Text

Restricted Access

About the authors

Inna V. Druk

Omsk State Medical University

Author for correspondence.
Email: drukinna@yandex.ru
ORCID iD: 0000-0001-8317-7765

Dr. Sci. (Med.), Associate Professor, Head of the Department of Internal Medicine and Family Medicine of Continuous Professional Education

Russian Federation, Omsk

Svetlana S. Safronova

Omsk State Medical University

Email: safronova.sv77@gmail.com
ORCID iD: 0000-0001-5852-2782

Assistant Professor, Department of Internal Medicine and Family Medicine of Continuous Professional Education

Russian Federation, Omsk

Ksenia A. Kulebakina

Clinical Diagnostic Center

Email: ksenia-114@mail.ru

Endocrinologist

Russian Federation, Omsk

References

  1. Irvine W.J., McCallum C.J., Gray R.S., Duncan L.J. Clinical and pathogenic significance of pancreatic-islet-cell antibodies in diabetics treated with oral hypoglycaemic agents. Lancet. 1977;1(8020):1025–7. doi: 10.1016/s0140-6736(77)91258-2.
  2. Buzzetti R., Tuomi T., Mauricio D., et al. Management of latent autoimmune diabetes in adults: A consensus statement from an international expert panel. Diabetes. 2020;69(10):2037–47. doi: 10.2337/dbi20-0017.
  3. Antar S.A., Ashour N.A., Sharaky M., et al. Diabetes mellitus: Classification, mediators, and complications; A gate to identify potential targets for the development of new effective treatments. Biomed Pharmacother. 2023; 168:115734. doi: 10.1016/j.biopha.2023.115734.
  4. Gatta E., Anelli V., Cimino E., et al. Autoimmune polyglandular syndrome type 4: experience from a single reference center. Front Endocrinol (Lausanne). 2023; 14:1236878. doi: 10.3389/fendo.2023.1236878.
  5. Frommer L., Kahaly G.J. Type 1 Diabetes and Autoimmune Thyroid Disease-The Genetic Link. Front Endocrinol (Lausanne). 2021; 12:618213. doi: 10.3389/fendo.2021.618213.
  6. Goodwin G. Type 1 Diabetes Mellitus and Celiac Disease: Distinct Autoimmune Disorders That Share Common Pathogenic Mechanisms. Horm Res Paediatr. 2019;92(5):285–92. doi: 10.1159/000503142.
  7. Ahlqvist E., Storm P., Käräjämäki A., et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet. Diab Endocrinol. 2018. 6(5): 361–369. doi: 10.1016/S2213-8587(18)30051-2.
  8. Мамедов М.Н., Канорский С.Г., Мкртумян А.М. и др. Обновленные европейские рекомендации по лечению сердечно-сосудистых заболеваний при сахарном диабете 2023: мнение российских экспертов. Международный журнал сердца и сосудистых заболеваний. 2023;11(40 Suppl. 1):3–51. [Mamedov M.N., Kanorsky S.G., Mkrtumyan A.M. et al. Updated European guidelines for the treatment of cardiovascular diseases in diabetes mellitus 2023: opinion of Russian experts. International Heart and Vascular Disease Journal. 2023;11(40 Suppl. 1):3–51. (In Russ.)]. doi: 10.24412/2311-1623-2023-40S1-3-51.
  9. Мамедов М.Н., Канорский С.Г., Арабидзе Г.Г. и др. Сердечно-сосудистые заболевания и управление рисками: стандарты при сахарном диабете 2023 (рекомендации АДА). Мнение российских экспертов. Международный журнал сердца и сосудистых заболеваний. 2023;11(40):5–27. [Mamedov M.N., Kanorsky S.G., Arabidze G.G. et al. Cardiovascular diseases and risk management: the standards in diabetes mellitus 2023 (ADA Recommendations). Opinion of the Russian. International Heart and Vascular Disease Journal. 2023;11(40):5–27. (In Russ.)]. doi: 10.24412/2311-1623-2023-40-5-27.
  10. Stone S.I., Balasubramanyam A., Posey J.E. Atypical Diabetes: What Have We Learned and What Does the Future Hold? Diab Care. 2024;47(5):770–81. doi: 10.2337/dci23-0038.
  11. Кононенко И.В., Смирнова О.М., Майоров А.Ю., Шестакова М.В. Классификация сахарного диабета. Всемирная организация здравоохранения 2019 г. Что нового? Сахарный диабет. 2020;23(4):329–39. [Kononenko I.V., Smirnova O.M., Mayorov A.Yu., Shestakova M.V. Classification of diabetes mellitus. World Health Organization 2019. What’s new? Diabetes Mellitus. 2020;23(4):329–39. (In Russ.)]. doi: 10.14341/DM12405.
  12. Classification and Diagnosis of Diabetes. Standards of Medical Care in Diabetes-2022. Diab Care. 2022; 45:S17–38.
  13. Дедов И.И., Шестакова М.В., Майоров А.Ю., ред. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Вып. 11. М., 2023. Доступно на: https://webmed.irkutsk.ru/doc/pdf/algosd.pdf. [Dedov I.I., Shestakova M.V., Mayorov A.Yu., eds. Algorithms of specialized medical care for patients with diabetes mellitus. Issue 11. M., 2023. (In Russ.)]. Available at: https://webmed.irkutsk.ru/doc/pdf/algosd.pdf.
  14. Stenström G., Gottsäter A., Bakhtadze E., et al. Latent autoimmune diabetes in adults: definition, prevalence, beta-cell function, and treatment. Diabetes. 2005;54(Suppl. 2):S68–72. doi: 10.2337/diabetes.54.suppl_2.s68.
  15. Carlsson S. Etiology and Pathogenesis of Latent Autoimmune Diabetes in Adults (LADA) Compared to Type 2 Diabetes. Front Physiol. 2019; 10:320. doi: 10.3389/fphys.2019.00320.
  16. Tuomi T., Groop L.C., Zimmet P.Z., et al. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes. 1993; 42:359–62. doi: 10.2337/diab.42.2.359.
  17. Zimmet P.Z., Tuomi T., Mackay I.R., et al. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diab Med. 1994; 11:299–303.
  18. Cousminer D.L., Ahlqvist E., Mishra R., et al. Bone Mineral Density in Childhood Study. First genome-wide association study of latent autoimmune diabetes in adults reveals novel insights linking immune and metabolic diabetes. Diab Care. 2018; 41:2396–403.
  19. Mishra R., Akerlund M., Cousminer D.L., et al. Genetic discrimination between LADA and childhood-onset type 1 diabetes within the MHC. Diab Care. 2020; 43:418–25.
  20. Löfvenborg J.E., Andersson T., Carlsson P.O., et al. Fatty fish consumption and risk of latent autoimmune diabetes in adults. Nutr Diab. 2014;4(10): e139. doi: 10.1038/nutd.2014.36.
  21. de Candia P., Prattichizzo F., Garavelli S., et al. Type 2 Diabetes: How Much of an Autoimmune Disease? Front Endocrinol (Lausanne). 2019; 10:451. doi: 10.3389/fendo.2019.00451.
  22. Stenström G., Gottsäter A., Bakhtadze E., et al. Latent Autoimmune Diabetes in Adults: Definition, Prevalence, β-Cell Function, and Treatment. Diabetes. 2005;54(Suppl. 2):S68–72. doi: 10.2337/diabetes.54.suppl_2.S68.
  23. Xiang Y., Huang G., Zhu Y., et al. China National Diabetes and Metabolic Disorders Study Group. Identification of autoimmune type 1 diabetes and multiple organ-specific autoantibodies in adult-onset non-insulin-requiring diabetes in China: A population-based multicentre nationwide survey. Diab Obes Metab. 2019;21(4):893–902. doi: 10.1111/dom.13595.
  24. Mishra R., Hodge K.M., Cousminer D.L., et al. A Global Perspective of Latent Autoimmune Diabetes in Adults. Trends Endocrinol Metab. 2018;29(9):638–50. doi: 10.1016/j.tem.2018.07.001.
  25. Pilla S.J., Balasubramanyam A., Knowler W.C., et al. Look AHEAD Research Group. Islet autoantibody positivity in overweight and obese adults with type 2 diabetes. Autoimmunity. 2018 ;51:408–16.
  26. Brooks-Worrell B., Hampe C.S., Hattery E.G., et al. GRADE β-cell Ancillary Study Network; GRADE Research Group. Islet autoimmunity is highly prevalent and associated with diminished β-cell function in patients with type 2 diabetes in the GRADE study. Diabetes. 2022; 71:1261–127.
  27. Wada E., Onoue T., Kinoshita T., et al. Adult-onset autoimmune diabetes identified by glutamic acid decarboxylase autoantibodies: a retrospective cohort study. Diabetologia. 2021;64(10):2183–92. doi: 10.1007/s00125-021-05516-1.
  28. Sørgjerd E.P. Type 1 Diabetes-related Autoantibodies in Different Forms of Diabetes. Curr Diab Rev. 2019;15(3):199–204. doi: 10.2174/1573399814666180730105351.
  29. Силко Ю.В., Никонова Т.В., Иванова О.Н. и др. Латентный аутоиммунный диабет взрослых: информативность аутоантител. Тер. архив. 2016;88(10):42–5. Doi: https://doi.org/10.17116/terarkh2016881042-45.
  30. Al-Majdoub M., Ali A., Storm P., et al. Metabolite profiling of LADA challenges the view of a metabolically distinct subtype. Diabetes. 2017; 66:806–14. doi: 10.2337/db16-0779.
  31. Zhou Z., Xu M., Xiong P., et al. Prognosis and outcome of latent autoimmune diabetes in adults: T1DM or T2DM? Diab Metab Syndr. 2024;16(1):242. doi: 10.1186/s13098-024-01479-6.
  32. Siddiqui K., Nawaz S.S. Exploration of Immune Targets for Type 1 Diabetes and Latent Autoimmune Disease Immunotherapy. Immunotargets Ther. 2023;12:91–103. doi: 10.2147/ITT.S417917.
  33. Sorgjerd E.P., Asvold B.O., Thorsby P.M., Grill V. Individuals fulfilling criteria for type 2 diabetes rather than LADA display transient signs of autoimmunity preceding diagnosis with possible clinical implications: the HUNT study. Diab Care. 2018; 41: e161–3. doi: 10.2337/dc18-1069.
  34. Buzzetti R., Zampetti S., Maddaloni E. Adult-onset autoimmune diabetes: current knowledge and implications for management. Nat Rev Endocrinol. 2017; 13:674–86. doi: 10.1038/nrendo.2017.99.
  35. Maddaloni E., Coleman R.L., Agbaje O., et al. Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86). Lancet. Diab Endocrinol. 2020;8(3):206–15. doi: 10.1016/S2213-8587(20)30003-6.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Bionika Media